Phase II study of sunitinib malate following hepatic artery embolization for metastatic gastrointestinal neuroendocrine tumors.
Phase of Trial: Phase II
Latest Information Update: 13 Sep 2012
At a glance
- Drugs Sunitinib (Primary)
- Indications Gastrointestinal cancer; Liver metastases
- Focus Therapeutic Use
- 28 Feb 2012 Actual end date (Feb 2012) added as reported by ClinicalTrials.gov.
- 28 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Oct 2011 Planned End Date changed from 1 Dec 2011 to 1 Apr 2012 as reported by ClinicalTrials.gov.